The use of bevacizumab is increasingly reported in neuro-oncology. The most common schedule is 10 mg/kg every 2 weeks. We retrospectively investigated the efficacy of a 3-week schedule of 5 mg/kg bevacizumab in patients with recurrent glioblastomas. Fourteen patients (median age, 46 years) were included in the study. The median number of bevacizumab cycles was 4 (range, 2–8). Five patients (36%) had a partial response, 7 (50%) had stable disease, and 2 (14%) had progressive disease. No grade III-IV toxicities were observed. The median progression-free and overall survival were 3.6 months and 6.4 months, respectively. Every-3-week low-dose single-agent bevacizumab showed substantial activity and a safe profile in patients with recurrent glioblastoma.
StuppR., MasonW.P., van den BentM.J., WellerM., FisherB., TaphoornM.J., BelangerK., BrandesA.A., MarosiC., BogdahnU., CurschmannJ., JanzerR.C., LudwinS.K., GorliaT., AllgeierA., LacombeD., CairncrossJ.G., EisenhauerE., MirimanoffR.O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352: 987–996, 2005.
2.
WellerM., CloughesyT., PerryJ.R., WickW.: Standards of care for treatment of recurrent glioblastoma — are we there yet?Neuro Oncol, 15: 4–27, 2013.
3.
ChamberlainM.C.: Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined?CNS Drugs, 25: 815–818, 2011.
4.
SoffiettiR., TrevisanE., BerteroL., BosaC., RudaR.: Anti-angiogenic approaches to malignant gliomas. Curr Cancer Drug Targets, 12: 279–288, 2012.
5.
NordenA.D., YoungG.S., SetayeshK., MuzikanskyA., KlufasR., RossG.L., CiampaA.S., EbbelingL.G., LevyB., DrappatzJ., KesariS., WenP.Y.: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology, 70: 779–787, 2008.
6.
PopeW.B., LaiA., NghiemphuP., MischelP., CloughesyT.F.: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology, 66: 1258–1260, 2006.
7.
MacDonaldD.R., CascinoT.L., ScholdS.C., CairncrossJ.G.: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol, 8: 1277–1280, 1990.
8.
FriedmanH.S., PradosM.D., WenP.Y., MikkelsenT., SchiffD., AbreyL.E., YungW.K., PaleologosN., NicholasM.K., JensenR., VredenburghJ., HuangJ., ZhengM., CloughesyT.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol, 27: 4733–4740, 2009.
9.
KreisiT.N., KimL., MooreK., DuicP., RoyceC., StroudI., GarrenN., MackeyM., ButmanJ.A., CamphausenK., ParkJ., AlbertP.S., FineH.A.: Phase II trial of single agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol, 27: 740–745, 2009.
10.
RaizerJ.J., GrimmS., ChamberlainM.C., NicholasM.K., ChandlerJ.P., MuroK., DubnerS., RademakerA.W., RenfrowJ., BredelM.: A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer, 116: 5297–5305, 2010.
11.
ChamberlainM.C., JohnstonS.K.: Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol, 96: 259–269, 2010.
12.
KellyP.J., Daumas-DuportC., KispertD.B., KallB.A., ScheithauerB.W., IlligJ.J.: Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg, 66: 865–874, 1987.
13.
ZunigaR.M., TorcuatorR., JainR., AndersonJ., DoyleT., EllikaS., SchultzL., MikkelsenT.: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol, 91: 329–336, 2009.
14.
QuantE.C., NordenA.D., DrappatzJ., MuzikanskyA., DohertyL., LafrankieD., CiampaA., KesariS., WenP.Y.: Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol, 11: 550–555, 2009.
